Modern medicine faces challenges that didn't exist when current curricula were designed. Chronic disease dominates healthcare spending. Patients live longer and accumulate multiple conditions. Nutrition misinformation is widespread. Data and statistics guide nearly every medical decision. Technology increasingly shapes diagnosis and treatment. Physician burnout is rising sharply.​

Yet medical training still emphasizes memorization of disease and treatment,` rather than prevention, thinking in terms of systems,and fully utilizing life-long data records. A modern curriculum should shift from reactive medicine to preventive, systems-based, and data-driven medicine.

Statistics are the language of modern medicine:

Every clinical decision relies on probability, risk, and statistical interpretation. Physicians must interpret clinical trials, risk-benefit ratios, screening test accuracy, epidemiology, and treatment effectiveness. Yet Buchwald's review found that statistics is rarely a required course in medical school. Even at elite institutions, it's often merely "recommended" as pre-medical preparation.

Historically, students learned calculus but not probability or statistical reasoning. As a result, many physicians rely on research they don't fully understand how to evaluate. Without the ability to critically evaluate medical literature independently, evidence-based medicine becomes impossible.
Medical students should complete applied biostatistics, research interpretation, risk communication, Bayesian reasoning, and evidence quality assessment as basic requirements.

Nutrition is medicine's largest preventable risk factor:

Diet drives obesity, type 2 diabetes, cardiovascular disease, fatty liver disease, some cancers, and autoimmune and inflammatory disorders. The global weight-loss industry exceeds $300 billion annually, and patients constantly receive conflicting nutrition advice. Yet only one of the surveyed medical schools offered a dedicated nutrition course.

Many physicians graduate with minimal training in metabolism or dietary intervention. Doctors cannot guide patients if they're not adequately educated about nutrition. Medical education should include metabolism and energy balance, dietary patterns and chronic disease, nutritional counseling skills, and public nutrition misinformation literacy.

Preventive public health would end the artificial divide:

Medicine treats individuals. Public health treats populations. This division made sense historically, but in modern healthcare it's increasingly harmful. Pandemics, chronic disease prevention, environmental exposures, and lifestyle risks blur the boundary between individual and population health. Despite this reality, most medical schools still separate public health from clinical training.
Public health and medicine should be integrated. Epidemiology should be a part of basic clinical knowledge, alongside environmental health literacy, pandemic preparedness, and preventive medicine training. Prevention should become a central physician skill, not a peripheral specialty.

Bioengineering and technology are transforming medicine into a tech profession:

Modern physicians work with implantable devices, advanced imaging, wearables and remote monitoring, AI diagnostics, and robotics. Biology increasingly intersects with engineering, physics, and computing. Yet bioengineering is rarely taught to medical students.

Understanding how medical technology works improves clinical decision-making, patient safety, innovation, and collaboration. Basic medical training should include biomedical engineering fundamentals, medical device literacy, digital health technologies, and AI and machine learning basics. Future physicians must be partners in innovation, not passive users of technology.

Older adults (65+) are the fastest-growing segment of the patient population.

The demographic reality is stark. Approximately 18% of Americans are over 65, nearly 40% of healthcare spending is devoted to this group, and fewer than 7,000 geriatricians serve a nation of over one million physicians (in the U.S.). Most patients treated by physicians today have multiple chronic conditions, polypharmacy (the concurrent use of five or more medications), and age-related physiological changes. Yet geriatrics receives minimal curricular attention.

All physicians need training in polypharmacy and drug interactions, frailty and fall risk, cognitive decline, end-of-life care, and age-specific lab interpretation. Geriatric medicine should be an essential part of training, not optional.

Medical history and professional identity:

Medical education rarely teaches the history of medicine, yet historical perspective provides ethical context, reveals how knowledge evolves, encourages humility and critical thinking, and strengthens professional identity. Understanding the past helps physicians navigate uncertainty and change.
Curricula should include the history of medical discovery, the evolution of medical ethics, and lessons from past epidemics and breakthroughs. Medicine is not just a science — it's a centuries-long human endeavor.​

The Flexner Report transformed medical education once before. Today, medicine faces another turning point. Chronic disease, aging populations, technological disruption, and information overload demand a new kind of physician — one trained not only to treat disease, but to understand systems, data, prevention, and human behavior.​

Updating medical curricula is not merely an academic exercise. It's essential for the future of healthcare. The next generation of physicians must be trained for the world they will practice in, not the one medicine has left behind.

But this will surely present a major obstacle as medical schools attempt to make these changes, because of the way that physicians are currently trained — there's a memorization paradox.
Although modern medical schools officially emphasize critical thinking, clinical reasoning, problem-based learning, and evidence-based medicine, real-world outcomes do not accurately reflect that goal. Most have redesigned their curricula around small-group case learning, systems-based teaching, and early clinical exposure. On paper, medical education moved away from "memorize textbooks" decades ago. However, the reality of students' experience is quite different.

In practice, students must still learn an enormous volume of information including anatomy, physiology, biochemistry, pharmacology, pathology, microbiology, and clinical guidelines. The amount of required knowledge is so large that memorization becomes unavoidable, especially in the preclinical years. Students often describe the reality as "understanding is ideal, but memorization is required to pass." This tension exists because licensing exams like the USMLE still test thousands of facts, rare diseases, drug mechanisms, and biochemical pathways. Even when exams attempt to test reasoning, they require huge knowledge recall, creating powerful incentives for students to prioritize memorization.

Medical training today operates as a hybrid system. Memorization remains heavy during early training, while understanding increases during clinical years, and pattern recognition dominates in residency and actual practice. Students often use tools like Anki flashcards for thousands of facts daily, leading to the perception of "rote memorization." Clinical expertise ultimately relies on pattern recognition and mental libraries of cases, so memorization becomes the foundation of clinical intuition rather than an end in itself.

Medical schools are attempting to shift toward more clinical reasoning earlier through case-based learning, simulation labs, integrated curricula that teach anatomy, physiology, and pathology together, and more active learning with fewer traditional lectures. However, change is slow because licensing exams still require massive knowledge recall, creating what educators call "assessment drives learning" — students study to pass the exam, and schools teach toward the exam. The tension between the volume of knowledge medicine requires and the desire to develop true clinical reasoning remains one of the biggest debates in modern medical education.

Medical students find it necessary to resort to memorizing rather than learning and understanding most of the information that they're forced to remember, simply because they don't have sufficient time to allow them to understand what they are expected to repeat on tests. So if all the changes to medical school curricula suggested by Dr. Buchwald are actually attempted, the number of years required for receiving a medical degree will almost surely have to be extended significantly, especially if students are expected to actually learn the information, rather than memorize it.

1. Buchwald, H. (2026, January 30). Tweaking the Curriculum. Gastroenterology & Endoscopy News, https://www.gastroendonews.com/Opinions-and-Letters/Article/01-26/Medical-Curriculum-Innovation-and-Training-Reform/79404

A major new review published in The BMJ has concluded that calcium supplements, vitamin D supplements, or both taken together provide little to no meaningful protection against fractures or falls in older adults. The analysis pooled data from 69 randomized controlled trials involving nearly 154,000 people, and its conclusions were blunt — routine supplementation with calcium or vitamin D doesn't appear to prevent the fractures it's been promoted to prevent for decades (Massé et al., 2026).1

​The findings have been widely reported, and the medical establishment is once again debating whether guidelines recommending these supplements should be revised. What's largely missing from that debate, however, is an obvious question that keeps getting overlooked in study after study — if vitamin D can't be properly activated without adequate magnesium, and calcium can't be properly transported into bone without adequate vitamin D, what exactly are we measuring when we run these trials without first establishing whether the study subjects have enough magnesium?

The answer, it turns out, is that we may be measuring the performance of a system with a critical missing part, and then concluding that the parts we did supply don't work.​

Magnesium isn't a peripheral player in bone metabolism. It's a central one. Every enzyme involved in converting vitamin D into its biologically active form depends on magnesium as a cofactor. This includes the two key hydroxylase enzymes — 25-hydroxylase in the liver, and 1-alpha-hydroxylase in the kidneys — that carry out the sequential steps required to transform inactive vitamin D (either from supplements or sunlight) into the hormone-like compound the body can actually use (Uwitonze and Razzaque), 2018; Deng et al., 2025).2, 3​

A 2018 review published in The Journal of the American Osteopathic Association put it plainly — all of the enzymes that metabolize vitamin D appear to require magnesium, which acts as a cofactor in the enzymatic reactions in both the liver and kidneys (Uwitonze and Razzaque). The review's co-author, Mohammed S. Razzaque, PhD, a professor of pathology at Lake Erie College of Osteopathic Medicine, was equally direct — "Without magnesium, vitamin D is not really useful or safe." (American Osteopathic Association. 2018, February 26)4

The implications for calcium are just as significant. Vitamin D's primary job in bone health is to regulate the absorption of calcium from the intestine and control its transport into bone tissue. If vitamin D can't be activated because magnesium is inadequate, calcium absorption is impaired, regardless of how much calcium a person takes in. The calcium goes somewhere — but it may not go to bone. Research has shown that vitamin D supplementation can raise calcium and phosphate levels in the blood even when a person remains functionally vitamin D deficient, raising concerns about deposits in soft tissue and blood vessels when magnesium is too low to keep the process regulated (American Osteopathic Association. (2018, February 26).

​Magnesium also plays a direct role in bone structure and formation that doesn't depend on vitamin D at all. It makes up a component of bone mineral itself, it's required for the activation of alkaline phosphatase (an enzyme essential for forming new bone crystals), and it stimulates the activity of osteoblasts, the cells responsible for building bone (Qureshi, 2015).5 Magnesium depletion alone causes cessation of bone growth, decreased osteoblast activity, and bone fragility, independent of calcium or vitamin D status (US Patent 8,324,191).6

None of this is to say that vitamin D and calcium are useless. What the evidence suggests is that they don't work in isolation, and that the nutritional context in which they're taken matters enormously.
​
A person with adequate magnesium who takes vitamin D and calcium may well be supporting their bone health. A person who is magnesium deficient and takes the same supplements may see little benefit, and may actually be at increased risk of calcium depositing in the wrong places, such as the arteries and soft tissues, rather than in bone, because the regulatory machinery that vitamin D and magnesium together provide isn't functioning (American Osteopathic Association. 2018, February 26).

The BMJ review itself acknowledges that its findings may not apply to people receiving medication for osteoporosis or those with certain bone disorders. But it doesn't raise magnesium as a variable, even though the biochemistry is well established and the prevalence of magnesium deficiency in the study-age population is well documented.​

The researchers suggest that resources and attention be directed toward balance training, resistance exercise, and personalized fall prevention programs, which are all legitimate recommendations. What they don't suggest is that future trials should simply account for the magnesium status of their participants before they start, which seems like an obvious and inexpensive place to begin.

For those of us who are taking calcium and vitamin D supplements, or considering them, the practical takeaway from the emerging research isn't to stop. It's to ask whether we're completing the picture.
​
Vitamin D supplementation without adequate magnesium may leave a large portion of the vitamin D inactive and stored, unavailable to the body. Calcium supplementation without activated vitamin D to regulate its absorption and transport may not deliver calcium to bone effectively, and may carry its own risks if calcium ends up in the wrong tissues. Adding magnesium to the regimen, in a form the body can absorb, addresses the rate-limiting step that the trials continue to ignore.

Those of us with MC have additional reasons to pay attention to magnesium status. Chronic diarrhea depletes magnesium, and many of us tend to avoid many magnesium-rich foods, especially during flares. Some of us also take proton pump inhibitors, which are known to significantly reduce magnesium absorption. The combination of MC-related losses and inadequate dietary intake means that magnesium deficiency is likely to be much more prevalent in our group than in the general population.​

The conclusion that calcium and vitamin D don't prevent fractures may well be accurate for people who don't have enough magnesium to activate the system. What we're still waiting for is a large, well-designed trial that actually checks for magnesium deficiency before drawing any conclusions.

​Acknowledging that magnesium is essential for vitamin D to work, and that vitamin D is essential for calcium to reach bone, raises a practical question that needs to be addressed. Specifically, what amounts are appropriate for MC patients? The honest answer is that there is no single evidence-based dose that applies to everyone with MC, because requirements vary considerably depending on disease activity, diet, medication use, and blood levels. The information that follows is based on the ranges that the available evidence and the collective experience of the MC community support as reasonable starting points, not fixed recommendations.

Not all magnesium supplements are equivalent, and for MC patients this distinction is particularly important. Magnesium oxide, the form used most commonly in multivitamins because it's cheap and compact, has roughly one-quarter the bioavailability of organic magnesium salts, meaning much of what's on the label is never actually absorbed. To add insult to injury, it can have a laxative effect, which is the last thing most of us need.

Magnesium glycinate is generally the preferred form for MC patients. It's a chelated compound in which magnesium is bound to the amino acid glycine, which improves absorption through a separate intestinal pathway, and significantly reduces the laxative effect that makes other forms much more problematic for people who have inflammatory bowel disease (IBD)(Uwitonze, and Razzaque, 2018). ​

Magnesium citrate is also well absorbed but is more likely to loosen stools, which is useful for MC patients who have constipation-predominant symptoms, but counterproductive for those who have diarrhea-predominant MC. For those who find even magnesium glycinate tablets difficult to tolerate in larger doses, spreading smaller amounts throughout the day by sipping on an electrolyte solution achieves a similar effect with better individual tolerance.

When MC is active and diarrhea is ongoing, magnesium losses through the stool can be substantial. The body's stores are being depleted faster than a normal diet can replenish them, and malabsorption compounds the problem. A reasonable starting range for most MC patients with active disease is 200 to 400 mg of elemental magnesium per day, divided into two or more doses if possible. Some patients with more severe or persistent diarrhea may need 400 to 600 mg per day in order to maintain an adequate level, while others find that even the lower end of the range causes symptoms — particularly those who have impaired kidney function, low blood pressure, or arrhythmia sensitivity. For those individuals, caution with any magnesium supplementation is warranted.​

For vitamin D during active MC, the picture is similar, and standard recommended daily allowances (RDAs) are often insufficient. Chronic diarrhea reduces fat-soluble vitamin absorption, meaning the 600 to 800 IU (of vitamin D) that official guidelines recommend for the general public is unlikely to be even close to adequate for someone who has active IBD. Research in IBD patients has found that 5,000 IU of vitamin D3 daily is often required simply to achieve and maintain adequate serum levels during active disease, and some patients need more (Garcia, Moore, Kahan, and Hong, 2020).13 A study in IBD patients found that 2,000 IU per day produced a meaningfully larger improvement in vitamin D levels and disease activity scores than 1,000 IU per day — a finding consistent with the general principle that higher doses are needed when absorption is compromised (Garcia, Moore, Kahan, and Hong, 2020.

Once diarrhea has resolved, magnesium losses slow considerably, and many MC patients can maintain adequate status with 200 to 300 mg of elemental magnesium per day. Those who use proton pump inhibitors, which are known to reduce magnesium absorption across the intestinal wall, may need to stay at the higher end of that range or beyond. The same applies to anyone who has had bowel resections, has a history of osteoporosis or osteopenia, or experiences ongoing mild loose stools. These are all situations in which maintenance requirements remain elevated even without a full flare.​

For vitamin D dosing when the disease is in remission, a daily dose of 2,000 to 5,000 IU is the range most commonly supported by both the research literature and the practical experience of the MC community. The right dose within that range isn't determined by guesswork — it's determined by a blood test. A 25-hydroxyvitamin D test (commonly written as 25(OH)D) measures the storage form of vitamin D in the blood and is the standard way to assess vitamin D status. Most MC patients appear to do best when their level falls between 40 and 60 ng/mL (100 and 150 mmol/l). Some practitioners who specialize in IBD prefer a target of 50 to 70 ng/mL (125 to 175mmol/l). Levels substantially above 80 to 100 ng/mL (200 to 250 mmol/l) provide little additional benefit and begin to carry their own risks, so more is not always better once the level is adequate.

1. Massé, O., Mercurio, C. M., Dupuis, S., Sahwi, M. Al., Arruda, A., Dallaire, G., . . . Williamson, D. (2026). Calcium, vitamin D, or combined supplementation to prevent fractures and falls: systematic review and meta-analysis. BMJ, 393. e088050. Retrieved from https://www.bmj.com/content/393/bmj-2025-088050

2. Uwitonze, A. M. and Razzaque, M. S. (2018). Role of Magnesium in Vitamin D Activation and Function. The Journal of the American Osteopathic Association, 118(3). pp 181-189. Retrieved from https://pubmed.ncbi.nlm.nih.gov/29480918/

3. Deng, K., Liu, J., Miao, Y., Wang, G., Wang, X., Liu, S., and Yang, L. (2025).The effects of magnesium and vitamin D/E co-supplementation on inflammation markers and lipid metabolism of obese/overweight population: a systematic review and meta-analysis. Frontiers in Nutrition, 12. 1563604. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12433974/

4. American Osteopathic Association. (2018, February 26). Researchers Find Low Magnesium Levels Make Vitamin D Ineffective. PR Newswire, Retrieved from https://www.prnewswire.com/news-releases/researchers-find-low-magnesium-levels-make-vitamin-d-ineffective-300603613.html

5. Qureshi, I. (2015, September 24). Bone-Health Cofactors: New Science on Vitamin D, K2, Magnesium, and Zinc. Nutritional Outlook, 18(7). Retrieved from https://www.nutritionaloutlook.com/view/bone-health-cofactors-new-science-vitamin-d-k2-magnesium-and-zinc

​6. US Patent 8,324,191. Combined calcium, magnesium and vitamin d supplements. Retrieved from https://patents.google.com/patent/WO2010008976A2/en

7. Jackson, S. E., Smith, L., Grabovac, I., Haider, S., Demurtas, J., López-Sánchez, G. F., . . . Yang, L. (2018). Ethnic Differences in Magnesium Intake in U.S. Older Adults: Findings from NHANES 2005⁻2016. Nutrients, 10(12). 1901. Retrieved from https://pubmed.ncbi.nlm.nih.gov/30518025/

8. Linus Pauling Institute. (n.d.). Micronutrient Inadequacies in the US Population: an Overview. Oregon State University, Retrieved from https://lpi.oregonstate.edu/mic/micronutrient-inadequacies/overview

9. Grassroots Health. (2025, January 23). Significant Roles of Magnesium Plus 7 Factors Contributing to Deficiency. GrassrootsHealth Nutrient Research Institute, Retrieved from https://www.grassrootshealth.net/blog/7-factors-make-people-likely-magnesium-deficient/

10. Dai, Q., Zhu, X., Manson, J. E., Song, Y., Li, X., Franke, A. A., . . . Shrubsole, M. J. (2018). Magnesium status and supplementation influence vitamin D status and metabolism: results from a randomized trial. The American Journal of Clinical Nutrition, 108(6). pp 1249–1258. Retrieved from https://pubmed.ncbi.nlm.nih.gov/30541089/

11. Deng, X., Song, Y., Manson, J. E., Signorello, L. B., Zhang, S. M., Shrubsole, M. J., . . . Dai, Q. (2013). Magnesium, vitamin D status and mortality: results from US National Health and Nutrition Examination Survey (NHANES) 2001 to 2006 and NHANES III. BMC Medicine, 11, 187. Retrieved from https://pubmed.ncbi.nlm.nih.gov/23981518/

12. Izaks, G. J. (2007). Fracture prevention with vitamin D supplementation: considering the inconsistent results. BMC Musculoskeletal Disorders, 8. 26. Retrieved from https://pubmed.ncbi.nlm.nih.gov/17349055/

13. Chakhtoura, M., Bacha, D. S., Gharios, C., Ajjour. S., Assaad, M., Jabbour, Y., . . . El-Hajj Fuleihan, G. (2022).Vitamin D Supplementation and Fractures in Adults: A Systematic Umbrella Review of Meta-Analyses of Controlled Trials. The Journal of Clinical Endocrinology and Metabolism, 107(3). pp 882–898. Retrieved from https://pubmed.ncbi.nlm.nih.gov/34687206/

14. Garcia, P. M., Moore, J., Kahan, D., and Hong, M. Y. (2020). Effects of Vitamin D Supplementation on Inflammation, Colonic Cell Kinetics, and Microbiota in Colitis: A Review. Molecules, 25(10). 2300. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC7288056/

The inverted food pyramid moves away from refined grains as the dietary foundation and instead prioritizes whole foods, quality proteins, healthy fats, and micronutrient-dense options. Rather than building meals around bread, pasta, and cereal, this modern approach emphasizes foods that reduce inflammation and support healing, principles that are particularly relevant for managing MC. MC patients will benefit from fewer grain-related triggers.​

The traditional pyramid placed bread, cereal, pasta, and rice at its base, making them dietary staples. The inverted model removes grains from the foundation. This benefits MC patients (including those who are not deliberately using diet to control their symptoms) because not only is the gluten in wheat, barley, and rye a reaction trigger, but many of us react to oats. And even other grains such as corn and rice cause problems for some of us, due to the lectins and fermentable starches they contain. So deemphasizing grains will surely lower immune stimulation for MC patients.

The inverted food pyramid benefits MC patients because it reduces grain-driven immune activation, prioritizes protein for healing and bone protection, emphasizes anti-inflammatory fats, treats fiber as individualized rather than mandatory, and improves magnesium and micronutrient status. Most importantly, it aligns with the real lived experience of MC patients rather than imposing dietary ideology.​

For those navigating the challenges of microscopic colitis, this modern approach offers not just permission to eat differently, but a scientifically sound framework that supports healing, reduces symptoms, and respects individual needs. It replaces one-size-fits-all dietary philosophy with physiology-based flexibility — exactly what MC patients need.

Normal aging tends to be associated with fewer, weaker goosebumps, due to changes in hair follicles, skin, muscle, and autonomic nerves.​

Persistent or exaggerated goosebumps later in life may indicate increased autonomic or inflammatory activity rather than youthfulness.

An online article that was recently posted on Medscape discussed some issues that we should be aware of if we are older than 65, especially if we are considering using any of the GLP-1 receptor agonists (Lambrrg, E. (2026, February 3).1

GLP-1 receptor agonists such as semaglutide and tirzepatide have become among the most widely requested medications for weight loss and diabetes management. They can improve blood sugar control, reduce cardiovascular risk, and produce meaningful weight loss. However, in adults over age 65, the risk-benefit balance fundamentally changes.

​Aging brings several baseline vulnerabilities that interact dangerously with GLP-1 medications. Older adults experience reduced muscle mass and strength (sarcopenia), declining bone density, lower thirst response and kidney reserve, increased fall risk, higher rates of polypharmacy (commonly defined as the concurrent use of five or more medications ), and higher prevalence of frailty and malnutrition.
​
GLP-1 medications amplify several of these vulnerabilities because they reduce appetite, slow stomach emptying, promote rapid weight loss, and cause gastrointestinal side effects. The result is that older adults are far more prone to complications from the same effects that younger adults tolerate without difficulty.

Accelerated muscle loss
This is arguably the single most important concern. Weight loss from GLP-1 drugs does not selectively remove fat—it also reduces lean body mass, including muscle. After age 65, muscle loss accelerates naturally, and muscle is critical for balance, mobility, independence, fall prevention, and metabolic health. Rapid weight loss in older adults can push patients from independent to frail to fall-prone with surprising speed.

This progression leads to falls, hospitalization, disability, and loss of independence. Clinicians increasingly emphasize resistance training and high protein intake specifically to counter this risk. Unfortunately, many older patients on GLP-1 medications do not receive this guidance.

Bone loss and fracture risk
Rapid weight loss reduces the mechanical loading that keeps bones strong through reduced stimulation of bone formation, disruption of bone mineral balance, and loss of the muscle forces that protect bone. Evidence shows that older adults with diabetes using GLP-1 medications had approximately 12% higher fracture risk than those using other diabetes drugs, and hip fractures were more common in clinical trials of semaglutide.

This is especially concerning for postmenopausal women, patients with osteopenia or osteoporosis, and anyone with a history of falls. A hip fracture in an older adult is a major life-changing event, typically associated with high morbidity and mortality.

Dehydration and kidney injury
GLP-1 medications commonly cause nausea, vomiting, diarrhea, and reduced thirst and appetite. Older adults already have reduced thirst sensation, reduced kidney reserve, and higher baseline risk of dehydration. Even mild gastrointestinal symptoms can lead to severe dehydration, acute kidney injury, and hospitalization. This is one of the most common serious complications in older patients using GLP-1 drugs.

Malnutrition from appetite suppression
Older adults often tend to have a reduced appetite to begin with, and when using this class of drugs they may over-restrict calories once appetite drops, leading to protein deficiency, vitamin and mineral deficiencies, worsening frailty, immune suppression, and slower healing. Experts now recommend 60 to 90 grams of protein daily, dietitian involvement, and close nutritional monitoring (when using these drugs). This risk is often underestimated, but it can have profound consequences on our functional independence.

Hypoglycemia when GLP-1s are combined with other diabetes drugs
GLP-1 drugs alone rarely cause low blood sugar, but the risk rises significantly when combined with insulin or sulfonylureas. Older adults are especially vulnerable to hypoglycemia, which can cause falls, confusion, cardiac arrhythmias, and hospitalization. Medication regimens often need careful adjustment when GLP-1 therapy begins.

Neurologic symptoms and dizziness
Dizziness is one of the most common neurologic side effects in older users, and it can be caused by dehydration, orthostatic hypotension (a sudden, significant drop in blood pressure upon standing or changing positions), reduced calorie intake, or rapid weight loss. In older adults, dizziness significantly increases fall risk, creating a dangerous cycle where medication side effects directly threaten the independence the patient is trying to preserve.

Experts recommend regular lab monitoring (especially of kidney function), slower dose escalation, nutrition counseling, hydration goals of approximately 64 ounces daily, resistance training several times weekly, and avoiding compounded versions of GLP-1 drugs. Dose escalation should never occur until the current dose is well tolerated.

Absolute contraindications include personal or family history of medullary thyroid cancer, MEN2 syndrome, severe gastroparesis (delayed stomach emptying) or bowel obstruction, and end-stage renal disease or dialysis. Strong relative contraindications include moderate to severe dementia, chronic kidney disease stage 4, baseline frailty or sarcopenia, and severe osteoporosis or frequent falls. These conditions dramatically increase complication risk and may make GLP-1 therapy more harmful than helpful.

GLP-1 medications can be powerful and beneficial, even in older adults, but in this population the biggest risks are not cosmetic or metabolic—they are functional and structural. Muscle loss leads to frailty and falls. Bone loss leads to fractures. Dehydration leads to kidney injury. Malnutrition leads to decline and disability.

For older adults, the key question is not simply "Will this help me lose weight?" It is "Will this help me stay strong, stable, and independent?" When used in carefully selected patients with close monitoring, nutrition support, resistance training, and attention to hydration and protein intake, GLP-1 medications can be helpful. Without that supervision, they can unintentionally accelerate the very problems aging patients most want to avoid — loss of strength, loss of mobility, and loss of independence.

1. Lambrrg, E. (2026, February 3). Older Patients Have Specific Risks for GLP-1 Use. Medscape, Retrieved from, https://www.medscape.com/viewarticle/older-patients-have-specific-risks-glp-1-use-2026a10003bb